Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
July 11, 2024 07:23 AM EDTUpdated 09:52 AM
R&D
Pharma

Pfiz­er press­es for­ward with once-dai­ly GLP-1 pill in long-await­ed move

Kyle LaHucik

Senior Reporter

Pfiz­er is mak­ing a move on its obe­si­ty pipeline af­ter mul­ti­ple quar­ters of ques­tions from in­vestors and an­a­lysts.

The New York phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times